Table 5.
Association of Antidepressant Medication Type With Incident CVD Considering Antidepressant Type by the Age of Participants When Antidepressant Use was First Reported (≤62 Years vs >62 Years) in the ARIC Cohort Study
| Outcomes | ||||
|---|---|---|---|---|
| AF | HF | MI | Ischemic Stroke | |
| No. of events, total | 332 | 365 | 174 | 119 |
| Median follow‐up, overall (y) | 13.4 | 13.6 | 13.5 | 14 |
| Age ≤62, y | 20.1 | 20.2 | 20.8 | 20.9 |
| Age >62, y | 4.8 | 4.9 | 4.9 | 4.9 |
| HR (95% CI)a | ||||
|---|---|---|---|---|
| SSRI vs non‐SSRI, age ≤62 | 1.09 (0.79–1.50) | 1.00 (0.73–1.37) | 0.90 (0.58–1.41) | 0.76 (0.42–1.36) |
| SSRI vs non‐SSRI, age >62 | 1.16 (0.82–1.65) | 1.02 (0.72–1.43) | 0.93 (0.56–1.54) | 1.65 (0.88–3.10) |
| P‐value for interactionb | 0.78 | 0.96 | 0.94 | 0.06 |
Model=adjustment for vital exhaustion questionnaire, BMI, cigarette smoking, alcohol use, antihypertensive medications, diabetes mellitus, and the year of diagnosis. AF indicates atrial fibrillation; ARIC, Atherosclerosis Risk in Communities; BMI, body mass index; HF, heart failure; HR, hazard ratio; MI, myocardial infarction; SSRI, selective serotonin reuptake inhibitor.
a
HR for each outcome comparing the exposure of using SSRI medications as compared with non‐SSRI medications.
b
SSRI‐by‐age interaction P value.